AR085955A1 - Proteinas de union al antigeno - Google Patents
Proteinas de union al antigenoInfo
- Publication number
- AR085955A1 AR085955A1 ARP120101214A ARP120101214A AR085955A1 AR 085955 A1 AR085955 A1 AR 085955A1 AR P120101214 A ARP120101214 A AR P120101214A AR P120101214 A ARP120101214 A AR P120101214A AR 085955 A1 AR085955 A1 AR 085955A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen binding
- binding protein
- antibody
- egfr
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Que interactúan con el Receptor del Factor de Crecimiento Epidérmico (EGFR). Se describen también métodos para tratar distintos tipos de cáncer y otras enfermedades que comprende administrar una cantidad farmacéuticamente eficaz de una proteína de unión al antígeno al EGFR. Se divulga además insectos, célula huésped, composición farmacéutica, y un método para tratar o prevenir cáncer.Reivindicación 1: Una proteína de unión al antígeno caracterizada porque comprende Seq Id Nº 3. Reivindicación 3: La proteína de unión al antígeno de la reivindicación 1, caracterizada porque dicha proteína de unión al antígeno es un anticuerpo humano, un anticuerpo humanizado, un anticuerpo quimérico, un anticuerpo multiespecífico, o fragmento del mismo. Reivindicación 25: Una molécula de ácido nucleico caracterizada porque codifica para la proteína de unión al antígeno de acuerdo a cualquiera de las reivindicaciones 1, 5, 9, 14, ó 19 a 22.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161473014P | 2011-04-07 | 2011-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085955A1 true AR085955A1 (es) | 2013-11-06 |
Family
ID=46168610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101214A AR085955A1 (es) | 2011-04-07 | 2012-04-09 | Proteinas de union al antigeno |
Country Status (12)
Country | Link |
---|---|
US (1) | US8628773B2 (es) |
EP (1) | EP2694552B1 (es) |
JP (1) | JP5908972B2 (es) |
KR (1) | KR102001686B1 (es) |
CN (1) | CN103619881B (es) |
AR (1) | AR085955A1 (es) |
AU (1) | AU2012239997A1 (es) |
CA (1) | CA2831957A1 (es) |
MX (1) | MX2013011706A (es) |
SG (1) | SG194111A1 (es) |
TW (1) | TW201305213A (es) |
WO (1) | WO2012138997A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013181572A2 (en) * | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to panitumumab |
RU2652880C2 (ru) * | 2013-04-07 | 2018-05-03 | Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. | Антитело против рецептора эпидермального фактора роста |
TW201536810A (zh) * | 2013-07-15 | 2015-10-01 | Novo Nordisk As | 結合尿激酶纖維蛋白溶酶原活化物之抗體 |
EP3176185A1 (en) | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
BR112016025312A2 (pt) * | 2014-05-01 | 2017-10-17 | Genentech Inc | variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem |
AU2015266664B2 (en) * | 2014-05-30 | 2020-04-30 | Shanghai Henlius Biotech, Inc. | Anti-epidermal growth factor receptor (EGFR) antibodies |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
CN108472382A (zh) * | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
NZ743881A (en) | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
CN107987161B (zh) * | 2016-10-26 | 2021-04-16 | 泰州迈博太科药业有限公司 | 一种抗egfr单克隆抗体制剂 |
CN110494452B (zh) * | 2017-04-03 | 2023-08-25 | 豪夫迈·罗氏有限公司 | 结合steap-1的抗体 |
CA3118027A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd. | Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof |
EP4005593A4 (en) * | 2019-07-24 | 2023-08-16 | Sinocelltech Ltd. | MULTI-VARIABLE DOSE DELIVERY METHOD FOR USE IN THE TREATMENT OF CANCER IN WHICH EGFR IS STRONGLY EXPRESSED |
MX2023001556A (es) * | 2020-08-05 | 2023-03-08 | Dragonfly Therapeutics Inc | Anticuerpos que se dirigen a egfr y uso de los mismos. |
WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
US20240009318A1 (en) * | 2020-11-20 | 2024-01-11 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Modified egfr antibody with reduced affinity, drug conjugate, and use thereof |
WO2022104692A1 (en) * | 2020-11-20 | 2022-05-27 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Engineered antibody, antibody-drug conjugate, and use thereof |
CN114496063B (zh) * | 2022-01-13 | 2023-05-23 | 北京博康健基因科技有限公司 | 基于天然氨基酸序列的信号肽设计与二级结构从头算建模方法和装置 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5159012A (en) | 1991-11-29 | 1992-10-27 | Textile Rubber & Chemical Co., Inc. | Process for the manufacture of polyurethane elastomers |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
NZ253943A (en) | 1992-06-18 | 1997-01-29 | Genpharm Int | Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
DK0843961T3 (da) | 1995-08-29 | 2007-05-21 | Kirin Brewery | Kimærisk mus og fremgangsmåde til at producere samme |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
CA2332331A1 (en) | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
CN100497389C (zh) * | 2001-06-13 | 2009-06-10 | 根马布股份公司 | 表皮生长因子受体(egfr)的人单克隆抗体 |
CA2478169C (en) | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
RU2339647C2 (ru) * | 2002-08-19 | 2008-11-27 | Астразенека Аб | Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение |
US8465696B2 (en) | 2004-02-03 | 2013-06-18 | Polymer Technology Systems, Inc. | Dry test strip with controlled flow and method of manufacturing same |
WO2005108297A2 (en) | 2004-05-04 | 2005-11-17 | The Trustees Of Columbia University In The City Of New York | Carbon dioxide capture and mitigation of carbon dioxide emissions |
DE102004034141A1 (de) | 2004-07-15 | 2006-02-09 | Cognis Ip Management Gmbh | Verwendung von Lithiumsalzen von Fettalkoholsulfaten zum Reinigen von Bohrlöchern, Bohrgeräten oder Bohrklein |
MX2007009963A (es) | 2005-02-24 | 2007-09-26 | Amgen Inc | Mutaciones del receptor del factor de crecimiento epidermico. |
BRPI0609615A2 (pt) | 2005-04-01 | 2010-04-27 | Amgen Inc | métodos de predição da eficácia de tratamento de agente de ligação especìfica a egfr em tratamento de cáncer relacionado com egfr num sujeito, de tratamento do mesmo e de determinação da eficácia de tratamento em paciente |
KR20080003422A (ko) | 2005-04-14 | 2008-01-07 | 메르크 파텐트 게엠베하 | 종양 조직 내의 egfr 유전자의 증가된 복제수에 기초한항-egfr 항체 치료 |
WO2007006310A2 (en) | 2005-07-11 | 2007-01-18 | Sandal Consulting | Method of making data available to a pilot |
AR065687A1 (es) | 2007-03-13 | 2009-06-24 | Amgen Inc | Metodo para determinar la presencia o no de una mutacion k-ras y terapia con anticuerpos anti-egfr |
ES2426814T3 (es) | 2007-03-13 | 2013-10-25 | Amgen Inc. | Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr |
PE20091827A1 (es) * | 2008-04-11 | 2009-11-20 | Galaxy Biotech Llc | Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
2012
- 2012-04-06 US US13/441,742 patent/US8628773B2/en active Active
- 2012-04-06 KR KR1020137029210A patent/KR102001686B1/ko active IP Right Grant
- 2012-04-06 JP JP2014504022A patent/JP5908972B2/ja active Active
- 2012-04-06 CA CA2831957A patent/CA2831957A1/en not_active Abandoned
- 2012-04-06 CN CN201280022224.1A patent/CN103619881B/zh active Active
- 2012-04-06 EP EP12723768.3A patent/EP2694552B1/en active Active
- 2012-04-06 MX MX2013011706A patent/MX2013011706A/es not_active Application Discontinuation
- 2012-04-06 SG SG2013074703A patent/SG194111A1/en unknown
- 2012-04-06 AU AU2012239997A patent/AU2012239997A1/en not_active Abandoned
- 2012-04-06 WO PCT/US2012/032519 patent/WO2012138997A1/en active Application Filing
- 2012-04-09 TW TW101112502A patent/TW201305213A/zh unknown
- 2012-04-09 AR ARP120101214A patent/AR085955A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
SG194111A1 (en) | 2013-11-29 |
WO2012138997A1 (en) | 2012-10-11 |
EP2694552A1 (en) | 2014-02-12 |
KR102001686B1 (ko) | 2019-07-18 |
CN103619881B (zh) | 2017-07-28 |
MX2013011706A (es) | 2014-04-25 |
AU2012239997A1 (en) | 2013-10-17 |
CA2831957A1 (en) | 2012-10-11 |
JP5908972B2 (ja) | 2016-04-26 |
JP2014516250A (ja) | 2014-07-10 |
CN103619881A (zh) | 2014-03-05 |
KR20140033038A (ko) | 2014-03-17 |
TW201305213A (zh) | 2013-02-01 |
US8628773B2 (en) | 2014-01-14 |
EP2694552B1 (en) | 2017-10-11 |
US20120328511A1 (en) | 2012-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR085955A1 (es) | Proteinas de union al antigeno | |
PE20181092A1 (es) | Anticuerpos anti-pd1 y metodos de uso | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
CY1122476T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι) | |
BR112017003108A2 (pt) | anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno | |
AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
BR112012004823A8 (pt) | Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica | |
BR112018007046A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio. | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
AR073775A1 (es) | Anticuerpos biespecificos anti-vegf/anti- ang -2 | |
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
AR080794A1 (es) | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 | |
UA117294C2 (uk) | Імунокон'югат | |
PE20150605A1 (es) | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico | |
BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
AR083747A1 (es) | Anticuerpos anti-il-23 | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
CL2008002668A1 (es) | Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp. | |
AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |